Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199781 | 0.91 | GAA (0.46) | PTGDR2ENPP3ENPP1LMNACCKAR | |
| SCHEMBL15154929 | 0.87 | PTGDR2 (0.45) | PTGDR2SRCENPP3ENPP1LMNA | |
| SCHEMBL4397390 | 0.85 | PTGDR2 (0.48) | PTGDR2SRCENPP3ENPP1PIK3C3 | |
| SCHEMBL1889325 | 0.81 | PTGDR2 (0.47) | PTGDR2SRCENPP3ENPP1CCKAR | |
| SCHEMBL1772875 | 0.80 | PTGDR2 (0.50) | PTGDR2SRCLMNAGAA | |
| SCHEMBL7515939 | 0.78 | ENPP3 (0.50) | PTGDR2SRCENPP3ENPP1LMNA | |
| SCHEMBL1773016 | 0.78 | PTGDR2 (0.67) | PTGDR2LATS1HTR6CCKAR | |
| SCHEMBL25262262 | 0.77 | ENPP3 (0.42) | PTGDR2ENPP3ENPP1LMNAGAA | |
| SCHEMBL7513541 | 0.77 | PTGDR2 (0.43) | PTGDR2ENPP3ENPP1LMNALATS1 | |
| SCHEMBL31150779 | 0.77 | ENPP3 (0.42) | PTGDR2ENPP3ENPP1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | PTGDR2 3655/4885SRC 241/4885ENPP3 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.